Screening for hepatitis C virus (HCV) among key populations, people living with HIV and their partners who have unknown HCV status Infections and Infestations
Conditions
Interventions
The study will be implemented through two phases, i.e., Phase I (active study phase) and Phase II (routine HCVST delivery).
Phase I: This phase is comprised of a cross-sectional implementation scien
uses cascade metrics and visualization to measure the relative strength of linkage from HCV antibody reactivity to confirmation testing and direct-acting antiviral enrollment among those opting for HC
and conducts focus group discussions with a key population (KP) and people living with HIV (PLHIV) HCVST users to explore the relative acceptability and preferences for HCVST.
During phase I, HIV-neg
Sponsors
PATH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18 years of age or older 2. Unknown HCV status or not tested for HCV within the last 6 months 3. Agreed to provide consent for participation in the study 4. Have access to a reliable phone for follow-up (for those opting for unassisted HCVST)
Exclusion criteria
Exclusion criteria: Individuals who have been diagnosed with chronic HCV and are on treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of HCVST distribution models in reaching first-time HCV testers is measured using a cross-sectional survey in Phase I and an HCV testing e-log book in Phase II | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Acceptability of secondary HCVST distribution among KP who seek primary HCVST as part of the community distribution model is measured using a cross-sectional survey and HCV testing e-log book in Phase I 2. Linkage of those that test HCV antibody reactive to confirmatory testing, diagnosis, and treatment is measured using an e-logbook and client FGDs in Phase I and an e-logbook and online HCV risk screener in Phase II 3. Acceptability of and preferences for HCVST models are measured using a cross-sectional survey and FGDs with clients and providers in Phase I and an e-logbook in Phase II 4. Operational feasibility of integrating HCVST into HIV and harm reduction services is measured using FGDs with clients and providers in Phase I and IDIs with decision-makers in Phase II 5. Willingness to pay for routine provider-led anti-HCV testing and HCVST tests is measured using a cross-sectional survey in Phase I 6. Relative cost of the three HCVST distribution models as compared to routine provider-led anti-HCV testing is measured using an Excel worksheet in both Phases I and II | — |
Countries
Viet Nam
Outcome results
None listed